Status:

COMPLETED

Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome

Lead Sponsor:

The Canadian College of Naturopathic Medicine

Collaborating Sponsors:

Wakunaga Pharmaceutical Co., Ltd.

Dicentra Inc.

Conditions:

Irritable Bowel Syndrome

Digestive System Diseases

Eligibility:

All Genders

18-64 years

Phase:

PHASE1

PHASE2

Brief Summary

The Canadian College of Naturopathic Medicine is conducting a research study on Irritable Bowel Syndrome (IBS), a common condition in North America. It is a long term, recurring gastrointestinal disor...

Detailed Description

The purpose of this trial is to investigate the effects of the three strain probiotic, Kyo-Dophilus, on the symptoms associated with severe Irritable Bowel Syndrome. A previous pilot clinical trial id...

Eligibility Criteria

Inclusion

  • Male and female subjects aged 18-64.
  • A diagnosis of Irritable Bowel Syndrome as per ROME III criteria.
  • A classification of severe irritable bowel syndrome as indicated by the Irritable Bowel Severity Scoring System (score \>300).
  • Female subjects currently using an acceptable form of birth control who agree to maintain its use throughout the study (e.g. abstinence, oral contraceptives, barrier methods).
  • Subjects who agree to maintain their current eating habits throughout the study.
  • Ability to understand and sign the Informed Consent Form.

Exclusion

  • Female subjects who are breastfeeding, pregnant, or are open to becoming pregnant in the next three months
  • Subjects currently receiving medication for the treatment of IBS symptoms.
  • Subjects currently receiving natural health products for treatment of IBS symptoms will be eligible for inclusion in the trial is they agree to undergo a four week washout period.
  • Subjects currently experiencing nausea, fever, vomiting, bloody diarrhea or severe abdominal pain.
  • Subjects who are immune-compromised (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment).
  • Subjects currently receiving antibiotic therapy or antibiotic therapy within the previous month.
  • Subjects regularly (\>3 times weekly) consuming probiotics enriched products (e.g. probiotic enriched yogurts, Activia, etc…).
  • Subjects who have recently (\< 3 months) initiated dietary measures to control IBS symptoms, such as elimination of certain foods.
  • Subjects with a history of major or complicated gastrointestinal surgery.
  • Subjects with severe endometriosis.
  • Subjects with malignant tumors or subjects undergoing chemotherapy or radiation therapy.
  • Subjects with severe IBS that require medication for treatment of IBS symptoms.
  • Subjects with weight loss, anemia, inflammatory bowel disease, or celiac sprue, and family history of colorectal cancer.
  • Subjects exhibiting or indicating thoughts of suicide currently or in the past as based on patient screening interview by the investigator/clinician. Appropriate referral to a health care provider will be provided.
  • Subjects with known allergies to milk or milk based products.
  • Subjects using and/or have used antipsychotic or anticholinergic medication within the prior month, those with reported significant abnormalities on thyroid function tests, blood counts and serum chemistry.
  • Subjects 50 years or older who have been diagnosed with IBS and have not received a colonoscopy in the last five years.

Key Trial Info

Start Date :

June 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2014

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT01887834

Start Date

June 1 2013

End Date

July 1 2014

Last Update

March 17 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Canadian College of Naturopathic Medicine

Toronto, Ontario, Canada, M2K 1E2